866-997-4948(US-Canada Toll Free)

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 69 Pages


Global Markets Directs, \'Metastatic Adenocarcinoma of The Pancreas Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas. Metastatic Adenocarcinoma of The Pancreas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Adenocarcinoma of The Pancreas.
  • A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Adenocarcinoma of The Pancreas Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Adenocarcinoma of The Pancreas 7
Metastatic Adenocarcinoma of The Pancreas Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Products under Development by Companies 15
Companies Involved in Metastatic Adenocarcinoma of The Pancreas Therapeutics Development 16
Gilead Sciences, Inc. 16
MediGene AG 17
Nanotherapeutics, Inc. 18
Novartis AG 19
Oncolytics Biotech Inc. 20
Peregrine Pharmaceuticals, Inc. 21
Threshold Pharmaceuticals, Inc. 22
Axcentua Pharmaceuticals AB 23
Eleison Pharmaceuticals, Inc. 24
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Anti-Angiogenesis Agent 2C3 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
glufosfamide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
pelareorep - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TH-302 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
paclitaxel lipsomal - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Triapine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AUY-922 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
simtuzumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
siG-12D LODER - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PRI-724 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Drug Profile Updates 54
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Discontinued Products 66
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Dormant Products 67

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Table


Number of Products Under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2013 7
Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Gilead Sciences, Inc., H2 2013 16
MediGene AG, H2 2013 17
Nanotherapeutics, Inc., H2 2013 18
Novartis AG, H2 2013 19
Oncolytics Biotech Inc., H2 2013 20
Peregrine Pharmaceuticals, Inc., H2 2013 21
Threshold Pharmaceuticals, Inc., H2 2013 22
Axcentua Pharmaceuticals AB, H2 2013 23
Eleison Pharmaceuticals, Inc., H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 29
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Drug Profile Updates 54
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Discontinued Products 66
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Dormant Products 67

List of Chart


Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2013 7
Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 25
Assessment by Route of Administration, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Molecule Type, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *